Treatment with anti-IL-17 mAb did not affect the capacity of CD4+ T cells to respond to infection, as the frequency of cytokine-producing CD4+ T cells was not altered between mice treated with anti-IL-17 or isotype control mAb (Fig. 6b). The gene discussed is IL17A; the disease is infection.